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Steven A. Barkera*, Jimo Borjiginb, Izabela Lomnickaa and Rick StrassmancABSTRACT: We report a qualitative liquid chromatography–tandem mass spectrometry (LC/MS/MS) method for the simulta-
neous analysis of the three known N,N-dimethyltryptamine endogenous hallucinogens, their precursors and metabolites,
as well as melatonin and its metabolic precursors. The method was characterized using artiﬁcial cerebrospinal ﬂuid (aCSF)
as the matrix and was subsequently applied to the analysis of rat brain pineal gland-aCSF microdialysate. The method de-
scribes the simultaneous analysis of 23 chemically diverse compounds plus a deuterated internal standard by direct injection,
requiring no dilution or extraction of the samples. The results demonstrate that this is a simple, sensitive, speciﬁc and direct
approach to the qualitative analysis of these compounds in this matrix. The protocol also employs stringent MS conﬁrmatory
criteria for the detection and conﬁrmation of the compounds examined, including exact mass measurements. The excellent
limits of detection and broad scope make it a valuable research tool for examining the endogenous hallucinogen pathways in
the central nervous system. We report here, for the ﬁrst time, the presence of N,N-dimethyltryptamine in pineal gland
microdialysate obtained from the rat. Copyright © 2013 John Wiley & Sons, Ltd.
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In a recent review of 69 published studies reporting the detection
of purported endogenous hallucinogens [N,N-dimethyltryptamine
(DMT); 5-hydroxy-DMT (HDMT, bufotenine); 5-methoxy-DMT
(MDMT)] in humans (Barker et al., 2012), it was concluded that
compelling mass spectral evidence exists for the conﬁrmation of
their presence in certain human biological ﬂuids [cerebrospinal
ﬂuid (CSF; DMT and MDMT), blood (DMT and HDMT) and urine
(DMT and HDMT)]. There is as yet no deﬁnitive information as to
the possible normal or pathophysiological roles of DMT, HDMT
or MDMT in humans or other species owing, in part, to the lack
of comprehensive methods to detect and unequivocally conﬁrm
the presence of these compounds in biological tissues and ﬂuids
(Barker et al., 2012). Methodology to adequately assess their
synthesis and turnover, simultaneously monitoring their precur-
sors and metabolites, is also lacking.
Original interest in endogenous hallucinogens, and DMT in
particular, was motivated by the hypothesis that these com-
pounds had a biochemical role in the heterogeneous disease
state of psychosis, especially schizophrenia (for a review see
Barker et al., 1981a, Barker et al., 2012). More recently, interest
in DMT has been renewed owing to its characterization as a
ligand for the sigma-1 (Fontanilla et al., 2009; Su et al., 2009)
and trace amine receptors (Su et al., 2009). Recent studies
concerning the enzyme responsible for the biosynthesis of these
compounds have also drawn further attention. Although the en-
zyme for the synthesis of the DMTs, indole-N-methyltransferase
(INMT), was not thought to occur to any signiﬁcant extent in
brain (Thompson and Weinshilboum, 1998; Thompson et al.,Biomed. Chromatogr. 2013; 27: 1690–1700 Copyright © 2013 John1999), studies have now shown its presence in the central
nervous system, including the pineal gland (Cozzi et al., 2011),
motor neurons in the spinal cord (Mavlyutov et al., 2012; Cozzi
et al., 2011) and in the retina (Cozzi et al., 2011). While the en-
zyme is present in these tissues, there has yet to be a deﬁnitive
determination of whether DMT is actually synthesized in these
tissues and, if so, how it is utilized or released from the tissues
under normal or altered physiological conditions.Wiley & Sons, Ltd.
LC/MS/MS of endogenous DMTs in rat pineal gland microdialysateGiven the reported expression of INMT in the mammalian
pineal gland, the binding of DMT to the sigma-1 and trace amine
receptors, and the necessity for more comprehensive analytical
methodology to begin to assess the possible function of the
DMTs in vivo, we undertook to develop a protocol to screen for
the presence of the DMTs, their precursors and metabolites in
mammalian body ﬂuids and tissues. We describe here the appli-
cation of our method to rat pineal gland microdialysates using
liquid chromatography–tandem mass spectrometry (LC/MS/MS)
for the qualitative analysis of the three known endogenous hal-
lucinogens and of 20 compounds that constitute most of their
known precursors and major metabolites (Fig. 1), as well as
melatonin and its biochemical precursors. The method was
developed in artiﬁcial CSF (aCSF), which was used as the pineal
gland dialysate. The method described uses positive ion
electrospray ionization, monitoring the protonated molecular
ion (M+ 1+) of each targeted analyte and corresponding frag-
ment ions (multiple reaction monitoring). It also applies strin-
gent analytical criteria for the detection and conﬁrmation of
these compounds in this matrix, including exact mass determi-
nation using high-resolution MS. The developed protocol was
applied to pineal gland-aCSF-microdialysates obtained from
freely moving rats. These studies revealed, for the ﬁrst time,
the presence of DMT in pineal gland microdialysate obtained
from the rat.
Materials and methods
Animals
Adult (12weeks of age), male, Wistar rats, weighing 300–350 g
each, were obtained from Harlan Laboratories (Indianapolis, IN,
USA) and were housed in light–dark conditions of 12:12 h for
at least one week before experiments. Food and water wasFigure 1. Compou
Biomed. Chromatogr. 2013; 27: 1690–1700 Copyright © 2013 Jprovided ad libitum. All animal procedures were approved by
the University Committee on Use and Care of Animals at the
University of Michigan.Pineal microdialysis
Rats were implanted with linear microdialysis probes with a mo-
lecular weight cut-off of 13 kDa and a membrane length of
12–15mm, manufactured in-house, as described previously
(see Borjigin and Liu, 2008, for surgical techniques and probe
preparation). The linear probe traversed both the pineal gland
as well as superﬁcial layers of occipital cortex on either side of
the gland. The pineal location was ascertained in each rat by
the presence of melatonin in the dialysates (Borjigin and Liu,
2008). Following a recovery period of 2–3 days, animals were
placed in microdialysis chambers. The chambers consisted of
enclosed animal housing units equipped with their own lighting,
which was controlled by an on–off timer, and ﬁtted with a venting
fan. Sample collection was accomplished with the aid of a liquid
swivel. Pineal microdialysis was performed with aCSF solution
ﬂowing continuously through the pineal gland at 2μL/min for 2 h.
All sample collections were performed during daylight hours. Two
tubes of dialysate were collected, each of which contained 120μL
collected over 1h (2μL/min). The pineal dialysates were collected
in microcentrifuge tubes on ice, capped and stored at 80 °C for
2–4weeks prior to being shipped on dry-ice for further analysis.
Samples experienced a single freeze–thaw cycle prior to analysis.Analytical standards
The following compounds were obtained from a commercial
source (Sigma Aldrich, St Louis, MO, USA), and were of the highest
available purity (>98%): DMT, MDMT, HDMT, tryptamine (TA), N-
methyl-TA (NMT), 5-hydroxy-TA (serotonin; HTA), 5-hydroxy-N-nds examined.
ohn Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/bmc
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1692methyl-TA (HNMT), 5-methoxy-TA (MTA), 5-methoxy-N-methyl-TA
(MNMT), melatonin, tryptophan (TRP), 5-hydroxy-tryptophan
(HTRP), 5-hydroxy-N-acetyl-TA (HNATA), indol-3-acetic acid
(IAA), 5-hydroxy-IAA (HIAA) and 5-methoxy-IAA (MIAA). The
following compounds were synthesized (as noted) and their
structures and purity conﬁrmed (>98%) by LC/MS/MS: DMT-N-
oxide (DMTNO), HDMTNO, MDMTNO (N-oxides were prepared
as described by Fish et al., 1955), 1,2,3,4-tetrahydro-β-carboline
(THBC), 2-methyl-1,2,3,4-THBC (2MTHBC), 6-hydroxy-THBC
(HTHBC) and 6-methoxy-THBC (MTHBC) (β-carbolines were
prepared by Pictet–Spengler reactions of the corresponding
amines with formaldehyde according to the methods described
by Ho and Walker, 1964). The internal standard was α,α,β,β-
tetradeutero-5-methoxy-N,N-dimethyltryptamine (d4-MDMT)
and was kindly provided by Dr David Nichols (Purdue Univer-
sity). The structures of the target analytes are shown in Fig. 1.Solvents and reagents
Solvents for liquid chromatography (LC) were obtained from
Fisher Scientiﬁc (Fairlawn, NJ, USA) and were Optima grade
(0.1% formic acid in water, 0.1% formic acid in acetonitrile).Artiﬁcial CSF
Artiﬁcial CSF was prepared in Dr Borjigin's laboratory as
deﬁned by Alzet (http://www.alzet.com/products/guide_to_use/
cfs_preparation.html) and contained NaCl (148mM), KCl (3mM),
CaCl2 · 2H2O (1.4mM), MgCl2 · 6H2O (0.8mM), Na2HPO4 · 7H2O
(0.8mM) and NaH2PO4 · H2O (0.2mM). This solution was used in
the analyses for preparation of standards, method blanks and
spiked controls. The aCSF used for the mass spectral analyses
was from the same batch as used to perform the microdialyses.Instrumentation
Routine analyses were conducted using a Thermo (Thermo
Electron North America, West Palm Beach, FL, USA) Quantum
Access LC/MS/MS (triple quadrupole) system equipped with
Accela 600 pumps and a multiplexed Accela open autosampler/
injection system. Analyses were conducted using Thermo Scientiﬁc
software (LC Quan 2.7.0 20, Xcalibur 2.2 SP1).LC methods
Samples (aCSF dialysate obtained from rats, aCSF blanks, spikes
and controls) were injected (30μL) onto an Agilent (Santa Clara,
CA, USA) Zorbax Eclipse Plus C18, 3.0× 100mm, 3.5μm particle
size column ﬁtted with a 2.0μm pre-ﬁlter (Grace Davison,
Deerﬁeld, IL, USA). Chromatography of the components was ac-
complished using a gradient LC program: solvent A=water–
0.1% formic acid (Fisher Optima); solvent B = acetonitrile–0.1%
formic acid (Fisher Optima); 0–2min hold at 98% A–2% B,
2–6min changing to 50% A–50% B with a 1min hold, 7–8min
changing to 2% A–98% B with a 9min hold, 17–18min changing
to 98% A–2% B and holding for 6min before the next injection.
The ﬂow rate was 300μL/min throughout the analysis. The waste
divert valve was initiated from 0.0 to 1.3min post injection and
again at 15–24min.Copyright © 2013 John Wwileyonlinelibrary.com/journal/bmcMS methods
The chromatography system was coupled to an ambient tem-
perature electrospray ionization probe on the Quantum Access
system. For analytes of interest, precursor-to-product ion transi-
tions were established through direct infusion of neat standards
of each compound into the ion source. Analytical standards
(1μg/mL) were dissolved in water or methanol and co-infused
into the mass spectrometer with mobile phase to obtain optimal
signal and fragmentation patterns/information (see Table 1). The
sensitivity was optimized for each compound by manipulating
collision energy to achieve the best signals.
Relevant MS settings for the analysis are shown in Table 1. The
source conditions were set as follows: 4.0 kV ion spray voltage,
350 °C capillary temperature, sheath gas (N2) pressure of 50 psi.
The resolutions of Q1 and Q3 were set at unit mass. The dwell
time was 10ms for each multiple reaction monitoring transition.
The Quantum Access system used a tune ﬁle, established prior
to the analyses being initiated, for DMT as the tune compound.Limits of detection and conﬁrmation
Serial dilutions of standards in aCSF (n=4) were analyzed using
the Quantum Access LC/MS/MS system to determine the lowest
limit of detection (LOD) and conﬁrmation. All data were based
on a 30μL injection volume. Detection of the analyte was not
considered positive unless all necessary conﬁrmation criteria
were met: retention time match vs in-run standard and relative
retention time to internal standard (±1%), presence of
predetermined fragment ions (two to four for each compound,
not including the protonated molecular ion) and the agreement
of ion ratios for the analyte vs in-run reference standards, within
±25% relative. Signals for each ion were not considered as
detected unless they also exceeded 3 times baseline noise.Speciﬁcity
Both blank aCSF and pineal dialysates from rats were examined
for the presence of interferences. The target analytes were also
examined to determine if any cross-talk would occur between
the different compounds, since several of the analytes have
the same molecular formula.Sample preparation
No further preparation of the collected pineal dialysate, other
than thawing, was required. The internal standard (d4-MDMT),
dissolved in 90:10 mobile phase, was added (10μL) to each sam-
ple aliquot (50μL) to give a ﬁnal concentration of 10 ng/mL.
Samples were placed into injection vials, capped, mixed and
held at 4 °C in the dark in the injector tray during the entire
period of the analysis (less than 8 h).Additional conﬁrmation methods
Analyses for conﬁrmation of DMT employed different fragmen-
tation conditions than previously reported, generating four
fragment ions (58, 115, 143, 144m/z) rather than the typical
two ions (58 and 144m/z) for DMT (Kärkkäinen et al., 2005;
McIlhenny et al., 2011, 2012).
Additional conﬁrmation data for DMT, as well as other com-
pounds detected, were also obtained using a Thermo LC/Biomed. Chromatogr. 2013; 27: 1690–1700iley & Sons, Ltd.
Table 1. MS parameters for analytes and internal standard, average retention times and limits of detection
Analyte [M+ 1]+ Product
ion 1
CE1
(V)
Product
ion 2
CE2
(V)
Product
ion 3
CE3
(V)
Product
ion 4
CE4
(V)
Limit of
detection
(ng/mL)
Retention
time (min)
TRP 205.053 91.169 36 118.123 26 146.057 16 0.10 6.18
HTRP 221.053 106.204 32 134.095 24 162.048 16 203.996 7 0.30 5.50
IAA 176.043 77.214 39 103.140 32 130.098 15 0.40 8.03
HIAA 192.034 91.157 33 117.100 33 146.053 14 2.00 6.65
MIAA 206.036 117.101 33 145.043 28 160.036 15 0.06 7.87
THBC 173.072 77.206 38 143.040 29 144.067 13 0.05 6.66
2MTHBC 187.100 115.200 35 144.000 10 0.02 6.68
HTHBC 189.000 115.120 31 117.108 31 160.057 14 0.02 5.38
MTHBC 203.072 131.084 32 159.040 25 174.038 13 0.30 6.49
TA 161.092 115.110 33 117.106 24 144.075 10 0.30 6.31
HTA 177.078 115.124 27 117.120 28 160.049 11 0.40 5.45
MTA 191.079 130.089 35 159.035 21 174.046 10 0.40 6.47
NMT 175.000 132.000 10 144.000 10 0.02 6.45
HNMT 191.090 115.120 30 117.116 30 160.057 12 0.10 5.67
MNMT 205.089 130.113 38 159.038 24 174.053 12 0.03 6.47
DMT 189.000 58.000 13 144.080 16 115.175 40 143.134 30 0.03 6.56
HDMT 205.100 58.300 13 160.100 14 0.30 5.66
MDMT 219.100 58.100 26 174.100 13 0.25 6.70
DMTNO 205.100 117.100 27 144.100 16 0.02 6.80
HDMTNO 221.093 115.120 33 117.117 33 160.055 14 0.02 5.98
MDMTNO 235.127 130.107 43 159.051 27 174.054 13 0.08 6.82
Melatonin 233.089 130.110 41 159.049 26 174.052 13 0.05 7.68
HNATA 219.085 115.149 33 117.143 29 132.147 25 160.079 12 0.30 6.70
d4-MDMT 223.200 60.360 15 134.160 43 178.110 15 — 6.60
CE, Collision energy.
LC/MS/MS of endogenous DMTs in rat pineal gland microdialysateExactive OrbiTrap high-resolution mass spectrometer equipped
with Accela 1250 pumps and a multiplexed Accela open
autosampler/injection system. These analyses were performed on
selected samples chosen on the basis of analyte response (inten-
sity). Data were collected and processed using Thermo Xcalibur
2.2.0.48 and LC Quan 2.7.0 software. The OrbiTrap system was
tuned using the exact mass of caffeine (M+1+; 195.08037) as the
reference/lock mass. Spray voltage was 3.8 kV, capillary tempera-
ture was 300 °C, sheath gas (N2) was set to 25psi, and the source
heater temperature was 350 °C. The collision-induced-dissociation
function was disabled. The same type of LC column was used for
LC separation of the samples on the Thermo Exactive instrument
experiments as was used for the experiments conducted on the
QuantumAccess, but a different LC programwas utilized to further
assist in conﬁrmation: solvent A=water–0.1% formic acid (Fisher
Optima); solvent B= acetonitrile–0.1% formic acid (Fisher Optima);
0–1min hold at 90% A–10% B, 1–4min changing to 50% A–50% B
with a 1min hold, 6–7min changing to 2% A–98% B with a 9min
hold, 16–17min changing to 90% A–10% B and holding for 6min
before the next injection. The ﬂow rate was 300μL/min through-
out the analysis.169Analyte stability
All of the compounds examined were tested for stability in solu-
tion (artiﬁcial CSF) at 80 °C and 4 °C for up to 6months and at
ambient temperatures for at least 1week in the dark. Absolute
responses vs time were compared to determine changes in
concentration.Biomed. Chromatogr. 2013; 27: 1690–1700 Copyright © 2013 JResults and discussion
Compounds selected for analysis
The 23 compounds chosen for analysis represent a signiﬁcant
number of the known metabolites of tryptophan in biological
species. They also represent the compounds in the speciﬁc
pathways related to the potential formation and subsequent
metabolism of the three known endogenous DMTs. The ability
to monitor their precursors, metabolites, and related central
nervous system indoleamines, as well as the three DMTs,
simultaneously offers a signiﬁcantly broader opportunity to
assess the possible presence and role of these compounds
individually and as a group than has ever been conducted
before (Barker et al., 2012).
Each of the DMTs (DMT, HDMT, MDMT) is the biosynthetic
product of INMT acting on their respective precursors, TA, HTA
and MTA, yielding as intermediates NMT, HNMT and MNMT
(for reviews see Barker et al., 1981a, 2012). The DMTs may also
be enzymatically demethylated to yield the same mono-
N-methylated compounds. Several studies have also shown the
conversion of these precursors and metabolites to the correspond-
ing β-carbolines (THBC, 2MTHBC, HTHBC and MTHBC), occurring
either through condensation with formaldehyde or through a
common intermediate, also occurring during demethylation
(Barker et al., 1980, 1981a). THBC and MTHBC have been reported
as endogenous substances appearing in adrenal and pineal
glands, as well as other tissues (Shoemaker et al., 1978; Barker,
1982; Barker et al., 1984, 1979, 1981b; Kari et al., 1983; Beaton
and Morris, 1984). All of these precursors and products, exceptohn Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/bmc
3
Figure 2A. (A) Chromatogram of artiﬁcial CSF (aCSF) fortiﬁed with internal standard only (d4-MDMT). (B) Chromatogram of analytes fortiﬁed into aCSF.
(C) Multi-reaction monitoring ions selected for the detection and conﬁrmation of compounds found in pineal gland CSF microdialysate illustrating
retention times and ion ratios compared with reference standards.
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1694the β-carbolines, are substrates for monoamine oxidase (MAO),
yielding as a product the respective indoleacetic acids, IAA,
HIAA and MIAA. Metabolism of the corresponding primary, sec-
ondary or tertiary amines by MAO is the predominant pathway
for their degradation. However, the β-carbolines have been
shown to possess MAO inhibition activity.
Another major pathway for metabolism of the DMTs is forma-
tion of the corresponding N-oxides (DMTNO, HDMTNO and
MDMTNO). Inhibition of MAO in vivo greatly elevates the con-
centration of the N-oxides relative to the IAAs in the metabolism
of the DMTs, often making them the major metabolites (Sitaram
et al., 1987a–c; Sitaram and McLeod, 1990; Kärkkäinen et al.,
2005; McIlhenny et al., 2011, 2012; Riba et al., 2012). The N-oxides
are not substrates for monoamine oxidase (Barker et al., 1980,
1981a) and are excreted unchanged in urine (Sitaram et al.,
1987a–c).
Kynurenine metabolites of tryptophan or the corresponding
metabolites of the other indolamines were not included in this
assay. Recent data generated in vivo suggest that this pathway
is not relevant to the metabolism of DMT, and this is also antic-
ipated to be the case for the other DMTs (McIlhenny et al., 2011,
2012). Since the analytical study in this case was based onCopyright © 2013 John Wwileyonlinelibrary.com/journal/bmcdialysate obtained from the pineal gland, we also monitored
the presence of melatonin, HTRP and HNATA.Ion proﬁles and monitoring
The mass spectrometer (Quantum Access) settings required to at-
tain the best response and fragment ion information for each com-
pound analyzed are given in Table 1 and are typical for such
compounds on this type of instrument. Three compounds gave
at least two diagnostic ions while most of the compounds pro-
duced at least three ions for monitoring. Three of the compounds
analyzed gave four ions, in addition to the acknowledged source
of the ions being the monitored protonated molecular weight
ion [(M+1)+]. These protonated molecular ions, their product ions
and their ratios were used to assist in the identiﬁcation and conﬁr-
mation of the analytes. It should be noted that DMT typically gives
only two ions, 58+ and 144+ (Table 1) under previously reported
conditions, as observed by us and others (Kärkkäinen et al., 2005;
McIlhenny et al., 2011, 2012). However, to assist in the conﬁrma-
tion, special conditions for fragmentation were established for
the analysis, with DMT giving four diagnostic ions, 58+, 115+,
143+ and 144+ m/z (Table 1 and Fig. 3). The use of more fragmentBiomed. Chromatogr. 2013; 27: 1690–1700iley & Sons, Ltd.
Figure 2B. (Continued)
LC/MS/MS of endogenous DMTs in rat pineal gland microdialysateions was deemed necessary since the identiﬁcation of DMT has
been controversial (Barker et al., 2012) and low mass ions such as
58+ (m/z) are not always truly diagnostic.169Chromatography
Average retention time data for the analysis are shown in Table 1.
Representative chromatographic data for blank aCSF and ana-
lyte-fortiﬁed aCSF (10 ng/mL shown), demonstrating the tempo-
ral elution of the target analytes, using a representative ion
selected for detection for each compound, are shown in Fig. 2
(A and B), respectively. Representative results for compounds
detected in pineal microdialysate samples, illustrating the diag-
nostic ions, their ratios and retention times relative to reference
standards, are shown in Fig. 2(C).
The mobile phase gradient developed afforded the ability to al-
low salts, which are in millimolar concentrations in aCSF, to be
eluted to waste before actual ion proﬁle monitoring began, and
they were diverted in the ﬁrst 1.3min of the analyses. The use of
the waste diversion valve assists in keeping the cone and ion
source clean. This approach is common practice in LC/MS/MS anal-
ysis but was, in this case, also based on other published studies
monitoring neurotransmitters and related compounds in rat aCSF
microdialysates (Greco et al., 2013; Uutela et al., 2009). The LC
gradient, starting with a high water content (98% water–2%Biomed. Chromatogr. 2013; 27: 1690–1700 Copyright © 2013 Jacetonitrile), allowed the target analytes to be sufﬁciently retained
at the head of the column to permit the elution of salts to occur. As
would be expected, the acidic media of themobile phase lessened
solution ionization of some of the organic acids being analyzed
and produced longer retention times for some of them relative
to that observed for some of the bases. The acids, bases and am-
photerics represented by these 23 compounds were eluted in a
5–9min window in an order relatively consistent with their polari-
ties in the solvent gradient used. This afforded temporal separation
of most of the components of the analysis. All of the compounds
were resolved by the combination of time and mass.
The mobile phase was varied during the experiments to move
the compounds to shorter (more initial acetonitrile) or longer
(higher initial water content for a longer period) retention times
and to establish optimum conditions. Pineal dialysate samples
shown to be positive for some of the target analytes were treated
to demonstrate whether or not the retention time match persisted.
In every case the shift in retention times was matched by the
detected analyte (data not shown). A more organic initial condi-
tion/mobile phase gradient (90:10, water–acetonitrile) was subse-
quently used for the further conﬁrmation of the analytes using the
Exactive OrbiTrap mass spectrometer, creating different (shorter)
retention times for the analytes as conﬁrmed from reference stan-
dards. Matching of retention times in varying LC conditions is an
additional technique to assist in conﬁrmation of unknowns.ohn Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/bmc
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Figure 2C. (Continued)
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LC/MS/MS of endogenous DMTs in rat pineal gland microdialysateSelectivity and speciﬁcity
An examination of aCSF showed no interfering substances that led
to misidentiﬁcation or false detection (as established by the stated
criteria) of any of the target analytes. Pineal dialysate aCSF from
rats did show the presence of several of the target analytes as
endogenous substances, but did not show any detectable or
signiﬁcant interferences with these or other analytes. Cross-talk
between targeted analytes was also examined, since (1) HNMT
andMTA, (2) TRP, HDMT, DMTNO andMNMT, (3) DMT and HTHBC,
(4) MDMT and HNATA, and (5) HDMTNO and HTRP have, respec-
tively, the samemolecular formula and, thus, the same exact mass
and protonated molecular ion. However, there was adequate tem-
poral separation of the compounds and differences in mass and
mass fragment ion formation such that no detectable cross-talk/
interference for any of the compounds was observed. The method
as described and performed here suggests that it possesses a high
degree of selectivity and speciﬁcity.Analyte stability
All of the compounds examined were stable in solution (artiﬁcial
CSF) when stored at80 °C for up to 6months (longest time mea-
sured) and stable at 4 °C for the same period of time. All of the
compounds were stable at ambient temperatures for at least
1week in the dark.Figure 3. The detection of N,N-dimethyltryptamine (DMT) in samples 5332-
four diagnostic ions and the correct ion ratios (±25% relative) vs a DMT refe
Biomed. Chromatogr. 2013; 27: 1690–1700 Copyright © 2013 JLimits of detection
Limits of detection (LODs) ranged from 0.02 to 2.0 ng/mL (HIAA;
Table 1). Standards were analyzed between the range of
concentrations of 0.01–25 ng/mL to establish the LODs. The
limiting factor in each was the ability to observe the weakest
of the established diagnostic ions at a concentration giving a
response greater than 3 times baseline noise. The resulting data
suggest that the assay is capable of providing reliable analytical
results for these compounds with a high degree of sensitivity in
this matrix.
Detection, and especially quantitation, of these compounds
in tissue microdialysates is complicated by the dynamic aspects
of the microdialysis process itself (Chefer et al., 2009). Recovery
of the compounds to be analyzed, often called the extraction
fraction, relative recovery or probe efﬁciency, can be affected
by the type of probe, probe membrane, ﬂow rate, tissue
resistance and a number of other factors. For example, the
analyses using the system applied in this case showed that
the in vitro rate of probe recovery was 14% for 5-HT, 15% for
N-acetylserotonin and 12% for melatonin under our experi-
mental conditions (data not shown). This is in line with other
published studies. Several studies have also shown that IAA
and HIAA, two of the other compounds detected, are also
recovered in this same percentage range using a variety of
techniques (Kendrick, 1989). It may also be assumed that the
rate of in vitro DMT and TA recovery, the last two compoundsB 2Hr, nos 23 and 31 as determined by retention time, occurrence of all
rence standard spiked into aCSF at 0.5 ng/mL (ppb).
ohn Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/bmc
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chemistry of the remaining compounds examined, it is also
reasonable to assume that their recovery rate is in the same
range, with many being quite water-soluble or closely related
in physicochemical properties to the compounds detected. As
with any assay, the combination of recovery rate, inherent in
microdialysis techniques, and lack of adequate sensitivity may
combine to give a negative result.
The present protocol was established for the qualitative
analysis or screening of pineal microdialysate and, thus, was
not examined for matrix effects. While direct analyses as
described here provide a high degree of efﬁciency, they can also
lead to problems arising from the effects of co-eluting matrix
components. Such effects can enhance or suppress detectability.
This is a particular problem for quantitative analyses. Previous
quantitative studies analyzing rat aCSF dialysate for neurotrans-
mitters and related compounds have examined their methodol-
ogy for matrix effects. For example, Cannazza et al. (2012) found
no evidence for matrix effects in their assay and concluded that
this was due to the fact that an initial high water content mobile
phase and use of a diverter valve effectively eliminated inor-
ganic salts that often are the source of ion suppression. Potential
interference from proteins is also greatly reduced in microdialy-
sis samples, since the pineal dialysate, in this case speciﬁcally,
had to pass a dialysis probe with a molecular weight cut-off of
13 kDa. We suggest that future efforts directed towardFigure 4. Representative exact mass data for a DMT reference standard
Copyright © 2013 John Wwileyonlinelibrary.com/journal/bmcquantifying the compounds examined here initially screen
samples using the method described to ﬁrst determine which
of the many analytes can be conﬁrmed to be present. A suitable
method may then be developed that targets these analytes and,
thus, simplify the analysis. At that juncture, appropriate valida-
tion, including determination of probe recovery rates and matrix
effects, should be conducted.Method performance
The analytical procedure presented here is straightforward,
requiring, in our hands, no ﬁltration or dilution of the dialysate
for analysis. Such direct analysis limits the ability to gain sensitiv-
ity through the process of extraction and concentration. None-
theless, it avoids losses of some of the compounds vs others in
attempting to establish a comprehensive extraction protocol
for such a large number of chemically diverse compounds.
Further, we are typically dealing with a rather small sample size
(240μL as performed here), which also complicates the use of
complex extraction procedures. Such an approach seems ideal
for this matrix. We noted, however, that the use of a heated
electrospray probe caused signiﬁcant loss of signal and response
in the progression of samples. This problem was remedied by
using an ambient temperature setting on the probe and early
solvent diversion to waste.and the presumptive DMT peak observed in pineal gland perfusate.
Biomed. Chromatogr. 2013; 27: 1690–1700iley & Sons, Ltd.
LC/MS/MS of endogenous DMTs in rat pineal gland microdialysateAnalytes detected and not detected in rat CSF
Figure2(C) is illustrative of chromatograms of pineal microdialysate
samples, showing the major ions used for monitoring and
conﬁrming the analytes. The chromatograms for the analysis
of aCSF collected from pineal perfusion (Fig. 2C) show the
presence of the compounds HTA, melatonin, TRP, HNATA, HIAA,
IAA, TA and DMT. Not all of the compounds were detected at all
times in all samples. However, as expected, melatonin and HTA
were consistently detected in pineal dialysate samples. It is
important to note that samples positive for DMT were also
positive for its biosynthetic precursor TA and its terminal
metabolite IAA. This data illustrates the need to monitor
precursors and metabolites and the need to follow the affected
pathways of biosynthesis and degradation, especially with
changing conditions in experimentation.
Three additional representative chromatograms and ion
traces of samples collected by pineal gland perfusion of freely
moving rats conﬁrming the presence of DMT are shown in Fig. 3
and are compared with a reference standard for DMT. Figure 3
illustrates the matches obtained for the retention times, pres-
ence of four diagnostic ions and the matches for their ion ratios,
all meeting stated criteria for conﬁrmation.
Within the limits of the assay as described and for the small
number of samples examined here, there was no indication of
the presence of the other compounds analyzed. However, the
failure to detect many of these substances should not be taken
as evidence that they are not biosynthesized or present in the
pineal gland of the rat. In the present study, samples were only
collected from pineal gland for 2 h during day time. Longitudinal
studies or studies altering physiological conditions may show
different data. Nonetheless, despite the presence of the precur-
sor for their synthesis (HTA), no MTA, MNMT, MDMT, MDMTNO
or MIAA nor the corresponding β-carboline (MTHBC; pinoline)
was detected. Similarly, no HNMT, HDMT, HDMTNO or HTHBC
was detected, despite the presence of HTA. However, HIAA
was detected in most samples. Also, although TA was detected
in some samples as well as DMT, no THBC, NMT, 2MTHBC or
DMTNO was observed, although IAA, the terminal metabolite
for DMT, TA and NMT, was detected in most samples. Pharmaco-
logical intervention may alter these patterns.169Exact mass conﬁrmation of DMT and other detected com-
pounds in rat CSF
Additional conﬁrmation of the identity of detected analytes was
obtained using the Thermo Exactive mass spectrometer. Thus,
melatonin (calculated exact mass 233.12828amu/found
233.12849amu), HTA (177.10224/177.10214amu), TA (161.10732/
161.10735amu), IAA (176.07061/176.07057amu), HIAA (192.06552/
192.06511amu), TRP (205.09715/205.09711amu) and HNATA
(219.11280/219.11296amu) detected in samples were further con-
ﬁrmed, with their exact masses agreeing to within ±0.1–0.9ppm
and matching the retention time for the corresponding reference
standards (data not shown) using a modiﬁed LC program.
Figure 4 shows representative data obtained for the exact mass
measurement of a DMT standard and DMT peaks in rat pineal
microdialysate samples using the Thermo Exactive instrument
and a different LC program from that used in the screening of
samples using the Thermo Quantum Access instrument. Analysis
of samples for DMT by exact mass gave 189.13860 amu [(M+1)+]
compared with the calculated exact mass of 189.13866 amuBiomed. Chromatogr. 2013; 27: 1690–1700 Copyright © 2013 Jobtained for a DMT reference standard, occurring at the matching
retention time for DMT (Fig. 4).
Taken together, the retention time matches (using two differ-
ent LC methods), the presence of four ions generated by moni-
toring and fragmenting a molecule with a nominal protonated
molecular ion (m/z) of 189+ and the high-resolution matching
of the exact mass for this compound vs a reference standard
are all scientiﬁcally compelling evidence for the presence of
DMT in rat pineal gland microdialysate. As noted, DMT was not
detected in all samples, as melatonin and HTA were, and it is
possible that the presence of measurable levels of DMT may
be subject to yet undetermined physiological conditions or
changes as well as time.
DMT has previously been reported in human CSF collected by
lumbar puncture (Corbett et al., 1978; Smythies et al., 1979). Its
origin in this matrix remains unknown. DMT has also previously
been reported to be present in whole rat brain. In 2005, using a
sensitive LC/MS/MS approach, Kärkkäinen et al. (2005) reported
the presence of DMT at low pg/g levels (10 and 15pg/g) in two
whole rat brain samples analyzed from MAO-inhibitor treated
animals. In 1984 Beaton and Morris (1984), using GC/MS method-
ology, also reported DMT as being present in whole rat brain in
low ng/g concentrations. This latter study illustrated changing
concentrations of DMT in whole brain with age of the animal
and also reported the detection of MDMT, THBC and TA. Thus,
the present research may be seen as corroborating these studies
with regard to DMT but is the ﬁrst such study to report the
presence of DMT in pineal gland and in live animals.Conclusions
The method described is a simple, sensitive, speciﬁc and direct
approach to the qualitative analysis of compounds in the trypto-
phan pathway related to the biosynthesis and metabolism of the
endogenous hallucinogens, or DMTs. The method involves the
direct injection of rat pineal gland aCSF microdialysate and anal-
ysis by LC/MS/MS, using stringent MS conﬁrmatory criteria,
including exact mass measurements. It is anticipated that the
same approach would also be viable for application to other
tissue perfusates, biological ﬂuids or samples with little or no
modiﬁcation. The excellent limits of detection, as well as the
capacity to perform qualitative analyses for a large number of
compounds in the tryptophan pathway simultaneously, without
requiring extraction, make it a valuable research tool, particularly
for examining the endogenous hallucinogen pathways in the
CNS. We report here for the ﬁrst time the presence of DMT in pi-
neal gland dialysate obtained from the rat. However, the
method will permit the conduct of a range of future experi-
ments, such as measuring possible circadian changes or
performing dialysis studies in other brain tissues or in the ventri-
cles. Regardless of the sample source, it is also important to be
able to assess the effects of pharmacological treatments, such
as MAO inhibition or other physiological interventions, on
changes in the presence or concentrations of DMT and the other
endogenous hallucinogens, their precursors and/or metabolites.
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